Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and...
Main Author: | Paul Hofman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/9/11/154 |
Similar Items
-
Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
by: Paul Hofman
Published: (2021-01-01) -
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
by: Paul Hofman
Published: (2017-08-01) -
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
by: Paola Ulivi
Published: (2016-07-01) -
Future Perspectives in Detecting <i>EGFR</i> and <i>ALK</i> Gene Alterations in Liquid Biopsies of Patients with NSCLC
by: Daniela Ferreira, et al.
Published: (2021-04-01) -
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01)